LOGIN  |  REGISTER
Terns Pharmaceuticals
Amneal Pharmaceuticals

Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference

May 03, 2022 | Last Trade: US$168.57 3.87 2.35

Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Global Healthcare Conference.

Details for the event are as follows:

Bank of America Merrill Lynch Global Healthcare Conference
Date: Tuesday, May 10, 2022
Time: 9:20am PDT
Webcast Link: https://bofa.veracast.com/webcasts/bofa/hc2022/id6InQpA.cfm

A webcast of the presentation will be available on the Investors section of the Company’s website for 90 days following the presentation.

About Krystal Biotech

Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing treatment options for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information, please visit http://www.krystalbio.com and follow @KrystalBiotech on LinkedIn and Twitter.

CONTACT:

Investors and Media:
Meg Dodge
Krystal Biotech
This email address is being protected from spambots. You need JavaScript enabled to view it.

Source: Krystal Biotech, Inc.


Chimerix

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page